Neurodegenerative Disease Management

Aims & Scope

Neurodegenerative Disease Management (ISSN: 1758-2024) presents findings, analysis and commentary in the ongoing battle with this range of debilitating illnesses.

The journal provides guidance to the multidisciplinary disease management community regarding the most effective treatment strategies and the implications of cutting-edge research as it emerges.

Topics covered include: All neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, ALS and multiple sclerosis Disease mechanisms Epidemiology Genetic and environmental influences on disease pathogenesis Clinical manifestations and diagnosis of disease Use of biomarkers in diagnosis and prognosis Use of technology to track symptoms and impact of treatment Therapeutic options Evaluation and management of cognitive impairment and dementia Prospects for new treatments such as cell and gene therapy Medical treatment guidelines Adverse events and drug safety Pharmacoeconomics, outcomes research, real-world evidence and quality of life Disease management in developed and developing countries Palliative care.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	3.4
2024	2.30

SJR (SCImago Journal Rank)

Year	Value
2024	0.896

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	36

Journal Rank

Year	Value
2024	5739

Journal Citation Indicator

Year	Value
2024	311

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• PubMed
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis

  Citation: 225

  Authors: Arnt V, Senda, Isabel, Peter, Theodoros, Laura

• Prevention of Falls in Parkinson’s Disease: A Review of Fall Risk Factors and the Role of Physical Interventions

  Citation: 166

  Authors: Colleen G, Serene S, Alice

• Parkinson’s Disease Psychosis: Presentation, Diagnosis and Management

  Citation: 150

  Authors: Ruth B, Julia, Irene H

• The sleep–wake Cycle and Alzheimer’s Disease: What do We know?

  Citation: 133

  Authors: Miranda M, Jason R, David M

• Activities of Daily Living: Where do They Fit in the Diagnosis of Alzheimer’s disease?

  Citation: 124

  Authors: Gad A, Rebecca E, Reisa A, Dorene M

• Collaborative Transdisciplinary Team Approach for Dementia Care

  Citation: 119

  Authors: James E, Licet, Yael

• Frontotemporal Dementia: diagnosis, Deficits and Management

  Citation: 115

  Authors: Nicholas T, Anneliese, Melanie L, Joel H

• Updates and Advances in Multiple Sclerosis Neurotherapeutics

  Citation: 113

  Authors: Moein, Carrie M

• Brain Insulin Resistance in Alzheimer's Disease and its Potential Treatment with GLP-1 Analogs

  Citation: 106

  Authors: Konrad

• Speech Disorders in Parkinson’s Disease: Pathophysiology, Medical Management and Surgical Approaches

  Citation: 104

  Authors: Khashayar, Ali, Jessica, Brianna

---